Unicycive Therapeutics (NASDAQ: UNCY) nets $16.3M from common stock sales

Rhea-AI Filing Summary

Unicycive Therapeutics, Inc. disclosed that, after June 30, 2025, it sold 3,549,846 shares of common stock under a sales agreement with Guggenheim Securities, LLC. The shares were sold at an average price of $4.56 per share, generating net proceeds of approximately $16.3 million for the company.

This at-the-market style equity financing increases Unicycive’s cash resources but also adds new shares to its common stock base. The filing does not detail specific uses for the funds, only that the proceeds were received by the company.

Insights

Biotech capital markets analyst

Unicycive raised about $16.3 million through at-the-market stock sales.

Unicycive Therapeutics sold 3,549,846 common shares at an average price of $4.56 per share under a sales agreement with Guggenheim Securities, LLC. This type of program typically allows a company to sell small blocks of stock into the market over time.

The transaction brings in cash proceeds of approximately $16.3 million, which can support operations or development activities, though specific uses are not described. The trade-off is increased share count, which can dilute existing holders. The filing characterizes this as activity subsequent to June 30, 2025.

false 0001766140 0001766140 2025-08-15 2025-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 15, 2025

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40582		81-3638692
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation or organization)				Identification No.)

4300 El Camino Real, Suite 210

Los Alto, CA 94022

(Address of principal executive offices)

Registrant’s telephone number, including area code: (650) 351-4495

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock		UNCY		Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Subsequent to June 30, 2025, pursuant to a sales agreement dated November 13, 2024 with Guggenheim Securities, LLC, Unicycive Therapeutics, Inc. (the “Company”) sold 3,549,846 shares of common stock at an average price of $4.56 per share, resulting in net proceeds to the Company of approximately $16.3 million.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 15, 2025

	UNICYCIVE THERAPEUTICS, INC.
	By:	/s/ Shalabh Gupta
		Shalabh Gupta
		Chief Executive Officer

2

FAQ

What financing did Unicycive Therapeutics (UNCY) report in this 8-K?

Unicycive reported selling 3,549,846 shares of common stock after June 30, 2025. The shares were sold under a sales agreement with Guggenheim Securities, LLC, providing approximately $16.3 million in net proceeds to the company.

How much cash did Unicycive Therapeutics (UNCY) receive from the stock sales?

The company received net proceeds of approximately $16.3 million from selling common shares. These funds came from issuing 3,549,846 shares at an average price of $4.56 per share under its agreement with Guggenheim Securities, LLC.

How many Unicycive (UNCY) shares were sold and at what average price?

Unicycive sold 3,549,846 shares of its common stock at an average price of $4.56 per share. These sales occurred after June 30, 2025, under a previously executed sales agreement with Guggenheim Securities, LLC.

What agreement did Unicycive Therapeutics (UNCY) use for these stock sales?

The company used a sales agreement dated November 13, 2024 with Guggenheim Securities, LLC. Under this agreement, Unicycive sold 3,549,846 common shares after June 30, 2025, generating approximately $16.3 million in net proceeds.

Does the Unicycive (UNCY) filing indicate who received the proceeds from the share sales?

Yes. The filing states that the sales of 3,549,846 common shares at an average price of $4.56 per share resulted in net proceeds of about $16.3 million to Unicycive Therapeutics, Inc. itself, not to selling stockholders.